Mamonkin et al., 2018 - Google Patents
Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T-cell malignanciesMamonkin et al., 2018
View HTML- Document ID
- 1710027226306318425
- Author
- Mamonkin M
- Mukherjee M
- Srinivasan M
- Sharma S
- Gomes-Silva D
- Mo F
- Krenciute G
- Orange J
- Brenner M
- Publication year
- Publication venue
- Cancer immunology research
External Links
Snippet
T cells expressing second-generation chimeric antigen receptors (CARs) specific for CD5, a T-cell surface marker present on normal and malignant T cells, can selectively kill tumor cells. We aimed to improve this killing by substituting the CD28 costimulatory endodomain …
- 210000001744 T-Lymphocytes 0 title abstract description 278
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mamonkin et al. | Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T-cell malignancies | |
| Li et al. | Enhanced cancer immunotherapy by chimeric antigen receptor–modified T cells engineered to secrete checkpoint inhibitors | |
| US20240124547A1 (en) | CHIMERIC ANTIGEN RECEPTORS (CARs) TARGETING HEMATOLOGIC MALIGNANCIES, COMPOSITIONS AND METHODS OF USE THEREOF | |
| US20240059754A1 (en) | Chimeric antigen receptors and enhancement of anti-tumor activity | |
| Carpenter et al. | B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma | |
| Zhang et al. | A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activity | |
| Cherkassky et al. | Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition | |
| US20240075070A1 (en) | Chimeric antigen receptor t cells targeting the tumor microenvironment | |
| Wang et al. | Preclinical evaluation of chimeric antigen receptors targeting CD70-expressing cancers | |
| Kim-Schulze et al. | Recombinant Ig-like transcript 3-Fc modulates T cell responses via induction of Th anergy and differentiation of CD8+ T suppressor cells | |
| Oda et al. | A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia | |
| Xu et al. | An engineered IL15 cytokine mutein fused to an anti-PD1 improves intratumoral T-cell function and antitumor immunity | |
| CN111247242A (en) | Chimeric Antigen Receptors (CARs), compositions and methods of use thereof | |
| WO2018132506A1 (en) | Chimeric antigen receptors based on alternative signal 1 domains | |
| Xu et al. | ILT3. Fc–CD166 interaction induces inactivation of p70 S6 kinase and inhibits tumor cell growth | |
| CN114634943A (en) | Compositions and methods for reprogramming TCRs using fusion proteins | |
| EP3347374A1 (en) | Ny-eso-1 specific tcrs and methods of use thereof | |
| JP2020513754A (en) | T cells engineered for cancer treatment | |
| CN107847585B (en) | NKT cell subsets for in vivo persistence and therapeutic activity and propagation thereof | |
| Drakes et al. | Optimization of T-cell receptor–modified T cells for cancer therapy | |
| Zhang et al. | Allogeneic CAR T cells targeting DLL3 are efficacious and safe in preclinical models of small cell lung cancer | |
| CN110461363B (en) | CD 37-targeting chimeric antigen receptor | |
| Zhang et al. | Immune evasion and therapeutic opportunities based on natural killer cells | |
| Shen et al. | Tigit-fc promotes antitumor immunity | |
| Yamaguchi et al. | Induction of tumor regression by administration of B7-Ig fusion proteins: mediation by type 2 CD8+ T cells and dependence on IL-4 production |